| Mr Joseph W Ippolito Jr, MD | |
|
526 Shoup Ave W, Suite F, Twin Falls, ID 83301-6050 | |
| (208) 736-7620 | |
| (208) 735-9537 |
| Full Name | Mr Joseph W Ippolito Jr |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 34 Years |
| Location | 526 Shoup Ave W, Twin Falls, Idaho |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306862792 | NPI | - | NPPES |
| 000010001696 | Other | ID | REGENCE BLUE SHIELD OF ID |
| DY066 | Other | ID | BLUE CROSS OF IDAHO |
| 003755600 | Medicaid | ID |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | M7008 (Idaho) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Visions Home Health & Visions Home Care Llc | Twin falls, ID | Home health agency |
| Hospice Visions | Twin falls, ID | Hospice |
| St Lukes Magic Valley Medical Center | Twin falls, ID | Hospital |
| Lost Rivers Medical Center | Arco, ID | Hospital |
| Serenity Healthcare | Twin falls, ID | Nursing home |
| Entity Name | Joseph W Ippolito Jr Md Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154561116 PECOS PAC ID: 5597822528 Enrollment ID: O20090318000713 |
News Archive
Loxo Oncology, Inc., a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced new results from its Phase 1 open-label, dose-escalation trial of LOXO-101, a selective inhibitor of tropomyosin receptor kinase (TRK) signaling molecules, and the first preclinical data for its RET and FGFR programs. The data are being presented at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.
Octapharma AG, one of the largest manufacturers of plasma products in the world, today announced that it has received orphan drug exclusivity approval for wilate® from the U.S. Food and Drug Administration (FDA).
Young women who are attracted to both sexes or who are unsure about who they are attracted to are more likely to develop an eating disorder than those attracted to only one sex, according to a new study from Drexel University.
Researchers used advanced two-color fluorescence cross-correlation spectroscopy to demonstrate the interaction between human ACE2 and the S1 subunit of SARS-CoV-2 and SARS-CoV.
Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today reported financial results for the first quarter of fiscal 2013 ended June 30, 2012.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Joseph W Ippolito Jr, MD 526 Shoup Ave W, Suite F, Twin Falls, ID 83301-5050 Ph: (208) 736-7620 | Mr Joseph W Ippolito Jr, MD 526 Shoup Ave W, Suite F, Twin Falls, ID 83301-6050 Ph: (208) 736-7620 |
News Archive
Loxo Oncology, Inc., a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced new results from its Phase 1 open-label, dose-escalation trial of LOXO-101, a selective inhibitor of tropomyosin receptor kinase (TRK) signaling molecules, and the first preclinical data for its RET and FGFR programs. The data are being presented at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.
Octapharma AG, one of the largest manufacturers of plasma products in the world, today announced that it has received orphan drug exclusivity approval for wilate® from the U.S. Food and Drug Administration (FDA).
Young women who are attracted to both sexes or who are unsure about who they are attracted to are more likely to develop an eating disorder than those attracted to only one sex, according to a new study from Drexel University.
Researchers used advanced two-color fluorescence cross-correlation spectroscopy to demonstrate the interaction between human ACE2 and the S1 subunit of SARS-CoV-2 and SARS-CoV.
Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today reported financial results for the first quarter of fiscal 2013 ended June 30, 2012.
› Verified 3 days ago
Blaine Gibby, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 730 N College Rd Ste A&b, Twin Falls, ID 83301 Phone: 208-814-8000 Fax: 208-933-4919 | |
Dr. Cathy White Canty, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 388 Martin St, Twin Falls, ID 83301 Phone: 208-734-0451 Fax: 208-734-0452 | |
Jonathan Muretisch, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 512 Pole Line Rd Ste 2, Twin Falls, ID 83301 Phone: 208-514-2500 Fax: 208-375-2217 | |
Marc Allan, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 512 Pole Line Rd Ste 2, Twin Falls, ID 83301 Phone: 208-735-3636 Fax: 208-735-3637 | |
Steven A. Kohtz, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 730 N College Rd, Suite A, Twin Falls, ID 83301 Phone: 208-814-7300 Fax: 208-933-4601 | |
Dr. Nichole S Halverson, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 526 Shoup Ave W Ste F, Twin Falls, ID 83301 Phone: 208-736-7620 | |
Mary Beth Curtis, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 730 N College Rd, Suite A, Twin Falls, ID 83301 Phone: 208-814-7300 Fax: 208-933-4601 |